US RAC Practice Exam
[Q]Which meeting is held with the FDA for the purpose of reaching concurrence on the key parameters of the investigational plan for a Class III device? [A] Agreement meeting [B] Determination meeting [C] Presubmission meeting [D] PMA Day-100 meeting - Answer- [A] Agreement meeting [Q]Which meeting held with the FDA is necessary for an otherwise stalled drug product development program to proceed? [A] Type A [B] Type B [C] Type C [D] Type D - Answer- [A] Type A [Q]Which type of meeting is held with the FDA for a Special Protocol Assessment? [A] Type A [B] Type B [C] Type C [D] Type D - Answer- [A] Type A [Q]Within how many days after FDA's receipt of a written request for a meeting should the following meetings occur: Type A, Type B, Type C [A] 15, 30, 45 [B] 30, 45, 60 [C] 30, 60, 90 [D] 30, 60, 75 - Answer- [D] 30, 60, 75 [Q]How often does a drug product listing need to occur? [A] Annually [B] Every June and December [C] Quarterly [D] Once - Answer- [B] Every June and December [Q]Upon receipt of a complete PMA, how many days does the FDA have to approve or not approve the PMA? [A] 90 [B] 120 [C] 150 [D] 180 - Answer- [D] 180 [Q]What is the one section that is required in an NDA but not in a BLA? [A] CMC [B] Clinical data [C] Field copy certification [D] Microbiology - Answer- [C] Field copy certification [Q]What are the possible outcomes to a PMA? [A] Approval, unacceptable, refusal [B] Acceptance, pending, rejected [C] Approval, Approvable, not approvable, denial [D] Approval letter, complete response letter, refuse to file letter - Answer- [C] Approval, Approvable, not approvable, denial [Q]What are the possible outcomes to an NDA? [A]Approval, unacceptable, refusal [B]Approval letter, complete response letter, refuse to file letter [C]Appro
Document information
- Uploaded on
- October 6, 2023
- Number of pages
- 27
- Written in
- 2023/2024
- Type
- Exam (elaborations)
- Contains
- Questions & answers